BLAINJECTIONINJECTABLE
Approved
Sep 2018
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
4
Mechanism of Action
Galcanezumab-gnlm is a humanized monoclonal antibody that binds to calcitonin gene-related peptide (CGRP) ligand and blocks its binding to the receptor.
Indications (2)
Clinical Trials (4)
Emgality for Migraine in Breastmilk
Started Feb 2024
30 enrolled
Migraine
A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine
Started Nov 2020
312 enrolled
Chronic Migraine
The Effect of Galcanezumab-gnlm on Post-Traumatic, Migrainous Headaches
Started Aug 2020
25 enrolled
Post-Traumatic Headache
A Study of Galcanezumab in Healthy Participants.
Started Jul 2016
160 enrolled
Healthy